ERBB2 and breast carcinoma: The Japan Breast Cancer Research Group conducted CREATE-X, a phase III clinical study of postoperative adjuvant chemotherapy with or without capecitabine (control) in patients who had a non-pCR after surgery and neoadjuvant chemotherapy of the HER2-negative primary breast cancer [23].